Biopharma’s Role in Transforming the Oncology Marketplace

This article was published in the Pharmaceutical Executive which can be accessed via https://www.pharmexec.com/view/biopharma-s-role-in-transforming-the-oncology-marketplace

Overview

Today, almost one-third of the industry pipeline is concentrated in oncology which is exciting for patients and caregivers. This article shares our perspectives on key trends shaping the oncology marketplace and how biopharma must adapt to stay focused on bringing personalized solutions to cancer patients. This approach highlights the following 8 key areas:

1. Advances in science and technology are driving the pace of innovation

2. Precision medicines are facilitating personalized solutions

3. The regulatory environment is conducive to advancing cancer treatments

4. The reliance on real-world evidence to support therapy decisions is increasing

5. Market access concerns linger while performance-based contracts are becoming mainstays

6. Artificial intelligence is driving significant improvements in care management

7. The social media ecosystems are positively impacting patient engagement

8. COVID environment is profoundly altering cancer care

Authors

• Subbarao Jayanthi, Managing Partner of RxC International

• William Smith, Management Consultant at RxC International

About RXC International

RxC International is a premier biopharma strategy consulting firm helping clients with growth strategies. The firm has deep expertise in new product planning and commercialization strategy. Our clients include leading pharmaceutical and biotechnology companies around the world. The firm has offices in New Jersey, Massachusetts, and California. Additional information about RxC International is available at www.RxCInternational.com.

If you have any questions or need additional information, please contact us at info@RxCinternational.com

Featured in the Pharmaceutical Executive in January 2023